Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

product recall

Sanofi reception

Sanofi pulls development of blood cancer drug

Fedratinib linked to brain disorder during clinical trials

- PMLiVE

EMA to review safety of Ariad’s Iclusig

Product information will be updated to warn of blood clot risk

- PMLiVE

FDA suspends sale of Ariad’s cancer drug

Iclusig linked to increased risk of blood clots

- PMLiVE

Change at the top as Levin leaves Teva

CEO resigns amid company-wide restructure

- PMLiVE

Novo Nordisk recalls insulin

Batches of prefilled NovoMix 30 pens found to have incorrect amount of diabetes treatment

- PMLiVE

Ariad tanks as Iclusig trial is halted on safety grounds

Shares fall after leukaemia patients develop blood clots

- PMLiVE

Communications rethink for Health Canada

Government review of regulator’s outreach efforts follows recall of birth-control drug

- PMLiVE

Union pressure delays Teva’s Israeli layoffs

Workforce cuts put on hold

- PMLiVE

Teva cuts 5,000 jobs to save $2bn a year by 2017

Israeli pharma company accelerates cost-reduction plans

- PMLiVE

Ariad halts patient enrolment for cancer drug studies

Concerns raised after patients taking Iclusig experience blood clots and cardiovascular events

- PMLiVE

Translational pharmacology and drug dosing

The key to ensuring safe and effective dosing

- PMLiVE

Teva defends Copaxone from Dutch patent challenge

Halts Mylan from marketing generic copy of MS drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links